Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Other Non Operating Income (2022 - 2025)

Kiniksa Pharmaceuticals International's Other Non Operating Income history spans 4 years, with the latest figure at $3.5 million for Q4 2025.

  • For Q4 2025, Other Non Operating Income rose 50.91% year-over-year to $3.5 million; the TTM value through Dec 2025 reached $11.6 million, up 23.07%, while the annual FY2025 figure was $11.6 million, 23.07% up from the prior year.
  • Other Non Operating Income reached $3.5 million in Q4 2025 per KNSA's latest filing, up from $3.1 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $3.5 million in Q4 2025 to a low of $34000.0 in Q1 2022.
  • Average Other Non Operating Income over 4 years is $1.9 million, with a median of $2.3 million recorded in 2024.
  • Peak YoY movement for Other Non Operating Income: surged 5288.24% in 2023, then decreased 2.07% in 2024.
  • A 4-year view of Other Non Operating Income shows it stood at $794000.0 in 2022, then skyrocketed by 198.36% to $2.4 million in 2023, then decreased by 2.07% to $2.3 million in 2024, then soared by 50.91% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Other Non Operating Income are $3.5 million (Q4 2025), $3.1 million (Q3 2025), and $2.7 million (Q2 2025).